profit from every $100 of sales.
$0$100
Jasper Therapeutics
We have no price for Jasper Therapeutics since 24 September 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.00-84.62% today
-99.8% in 1 year
1-year low $0.001-year high $0.14
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Jasper Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$75.8 million of profit last year.
SalesProfit
Jasper Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Jasper Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Jasper Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -51 | -69 | -76 | -84 | |
| -50 | -68 | -75 | -83 | |
| -38 | -64 | -71 | -76 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 48 | 95 | 80 | 36 |
| Cash | 38 | 87 | 72 | 29 |
| Total debt | 4 | 3 | 2 | 1 |
| Total liabilities | 12 | 16 | 18 | 32 |
| 36 | 78 | 62 | 4 | |
| – | – | – | – | |
| -102.0% | -67.0% | -94.9% | -1,230.4% | |
| -104.7% | -82.2% | -115.6% | -1,826.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -46 | -52 | -63 | -77 | |
| 1 | 0 | 1 | 0 | |
| -46 | -52 | -63 | -77 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 5 | 7 | 7 |
Valuation
- –
- –
- 0.10
- 4.3×
- 0.0×
- –
- 0.1×
- -31,653.6%
- -426.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -338.1%
- -347.3%
- -372.2%
- -211.9%
- -356.6%
- –
Growth
- –
- –
- −22.2%
- –
- +102.5%
Financial health
- 0.3×
- 0.30
- 3.5%
- –
- 2.62
- 2.62
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.04 | -0.49 | +91.8% |
| Mar 30, 2026 | -0.32 | -0.80 | +59.8% |
| Nov 10, 2025 | -0.00 | -1.21 | +99.9% |
| Aug 13, 2025 | -1.74 | -1.33 | −31.4% |
| May 12, 2025 | -1.41 | -1.35 | −4.6% |
| Dec 31, 2023 | -15.01 | – | – |
| Sep 30, 2023 | -0.00 | – | – |
| Jun 30, 2023 | -0.00 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
51No pass
Benjamin Graham
38No pass
Philip Fisher
42No pass
Peter Lynch
55No pass
Joel Greenblatt
100Pass
Charlie Munger
53No pass
Terry Smith
51No pass
Questions about Jasper Therapeutics
Is Jasper Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Jasper Therapeutics AI analysis
What does Jasper Therapeutics do?
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It is in Biotechnology.
Does Jasper Therapeutics pay a dividend?
No. Jasper Therapeutics does not pay a dividend at the moment.
How has Jasper Therapeutics stock done over the past year?
Down 99.8% over the past twelve months, to $0.00. It traded between $0.00 and $0.14 and is 99.9% below its high.
Who are Jasper Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Jasper Therapeutics's.
Prices: daily closes to Sep 24, 2026. Fundamentals: company reports via invest-like data.